IGF-1 LR3

Eighty-Three Residues, and What That Changes

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Regulatory frameworks treat an amino acid polymer of 40 residues or fewer as a peptide, regulated as a drug, and anything longer as a protein regulated as a biologic. IGF-1 LR3 is 83 residues, placing it firmly on the protein side.

Key facts

Threshold
40 amino acids
IGF-1 LR3
83 residues
Classification implied
Protein: biologic territory
For contrast, semaglutide
31 residues: a drug
Production
Recombinant, not synthetic
Consequence
Different impurity and folding concerns

Why the line falls where it does

Below roughly forty residues a molecule can generally be synthesised chemically and characterised completely, with every atom accounted for. Above it, synthesis becomes progressively impractical as coupling inefficiency compounds, and folding begins to determine function in ways analysis cannot fully capture. The threshold marks where complete characterisation stops being achievable.

Where this compound falls

Eighty-three residues, more than twice the threshold, with three disulfide bonds and a folded tertiary structure. It is produced by recombinant expression rather than solid-phase synthesis. That is not a coincidence; it is what a molecule of that size and complexity requires.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

What that changes about the impurities

Everything. A synthetic peptide accumulates deletion sequences from incomplete couplings, detectable by mass. A recombinant protein has none of those, because ribosomal synthesis does not fail that way. Instead it carries host cell proteins, host DNA and, from bacterial systems, endotoxin, none of which appears in a protein purity figure.

And what it changes about correctness

For a synthetic peptide, the right sequence is effectively the right molecule. For a folded protein with three disulfide bonds, the right sequence can still be the wrong molecule if the cysteines paired incorrectly, and a misfolded isomer has identical mass. Sequence correctness and molecular correctness separate at this size, and only above the threshold does that separation matter.

Why the classification is hypothetical here

IGF-1 LR3 holds no marketing authorisation anywhere, so no regulator has classified it. The point is what would apply if one did. It explains why the compound's documentation should look like a recombinant protein's rather than a peptide's, which is the practical consequence regardless of regulatory status.

The contrast within this catalogue

Semaglutide at 31 residues, tirzepatide and retatrutide at 39: all synthesisable, all fully characterisable, all handled as drugs. IGF-1 LR3 at 83 sits in a different technical world, and the difference shows up in how it is made, what can go wrong, and what a certificate needs to say. WADA class S2 applies to it regardless, at all times.

Quick reference

≤40 residuesIGF-1 LR3, 83 residues
Typical productionChemical synthesisRecombinant expression
Characteristic impurityDeletion sequencesHost protein, DNA, endotoxin
Folding a concern?RarelyYes, three disulfides
Detectable by mass?Impurities generally yesMisfolds no

Frequently asked questions

How long is IGF-1 LR3?

83 residues, more than twice the 40-amino-acid threshold that separates peptide from protein in regulatory frameworks.

Why does that matter practically?

It determines production route, impurity profile, and whether folding can go wrong independently of sequence.

Has a regulator classified it?

No. It holds no marketing authorisation anywhere. The point is what would apply, and what its documentation should therefore look like.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.